EP0151528B1 - 5-(amino or substituted amino)-1,2,3-triazoles - Google Patents

5-(amino or substituted amino)-1,2,3-triazoles Download PDF

Info

Publication number
EP0151528B1
EP0151528B1 EP85300520A EP85300520A EP0151528B1 EP 0151528 B1 EP0151528 B1 EP 0151528B1 EP 85300520 A EP85300520 A EP 85300520A EP 85300520 A EP85300520 A EP 85300520A EP 0151528 B1 EP0151528 B1 EP 0151528B1
Authority
EP
European Patent Office
Prior art keywords
amino
compound
alkyl
cyano
trichlorovinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP85300520A
Other languages
German (de)
French (fr)
Other versions
EP0151528A2 (en
EP0151528A3 (en
Inventor
Elbert E. Harris
Richard L. Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0151528A2 publication Critical patent/EP0151528A2/en
Publication of EP0151528A3 publication Critical patent/EP0151528A3/en
Application granted granted Critical
Publication of EP0151528B1 publication Critical patent/EP0151528B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Definitions

  • This invention relates to triazole compounds, their preparation, and their use.
  • Coccidiosis is a wide-spread poultry disease which is produced by infections of protozoa of the genus Eimeria which causes severe pathology in the intestines and caeca of poultry. Some of the most significant of these species are e. tenella, E. acervulina, E. necatrix, E. brunetti, E. maxima, E. mitis, E. mivati, E. hagani and E. praecox. This disease is generally spread by the birds picking up the infectious organism in droppings on contaminated litter or ground or by way of food or drinking water. The disease is manifested by hemorrhage, accumulation of blood in the caeca, passage of blood to the droppings, weakness and digestive disturbances. The disease often terminates in death, but the market value of fowls that survive severe infections is substantially reduced. Coccidiosis is therefore a disease of great economic importance and extensive work has been done to find new and improved methods for controlling and treating coccidial infections in poultry.
  • the invention is based on the discovery that certain 5-amino-1,2,3-triazoles and their substituted derivatives have a surprisingly and unexpectedly high degree of activity against coccidiosis of poultry. Certain of the compounds are novel.
  • R 1 is phenyl or phenyl-(C 1 - 3 alkyl), either unsubstituted or having from one to five halogen, cyano, trifluoromethyl, C 1-3 alkanoyl, nitro, C 1 - 3 alkyl, C 1 - 3 alkoxy, carboxy, alkyoxycarbonyl, trifluoromethoxy, acetamido, C 1 - 3 alkylthio, C 1-3 alkylsulphinyl, C 1-3 alkylsulphonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulphinyl and/or trifluoromethylsulphonyl substituents; or is phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthylmethyl, quinolyl or quinolylmethyl; R 2 is phenacyl, pyridyl, pyridylmethyl, naph
  • R 1 is a benzyl radical having a trichlorovinyl substituent and none, one or two substituents as defined above, all the substituents being in the meta or para position.
  • R 2 is amino
  • R 3 is carbamoyl
  • R 1 is phenyl or benzyl having one, two or three substituents that are halogen, cyano, trifluoromethyl, trichlorovinyl and/or methyl; especially di- or substituted phenyl or di- or tri-substituted benzyl in which the substituents are in the meta or para positions and are chloro, cyano, methyl, trifluoromethyl, or trichlorovinyl.
  • Examples of preferred compounds for anti-coccidial use in accordance with this invention are:
  • the C 1 - 3 alkyl groups comprise methyl, ethyl, propyl and isopropyl; the C 1-3 alkoxy groups comprise methoxy, ethoxy, propoxy, and isopropoxy; the C 1 - 3 alkanoyl groups comprise formyl, acetyl, and propionyl.
  • Administration of a small amount of at least one compound preferably by combination with poultry feed is effective in preventing or greatly reducing the incidence of coccidiosis.
  • the compounds are effective against both the caecal form (caused principally by E. tenella) and the intestinal forms (principally caused by E. acervulina, E. brunetti, E. maxima and E. necatrix).
  • the coccidiostats of this invention are particularly effective against the species that caused caecal damage in addition to preventing the pathology caused by the coccidia.
  • Compounds of the invention are also active against Eimeria spp, in other animals.
  • the compounds may be prepared by any one of several processes. The most general process is outlined in the following reaction scheme.
  • R 3 -methylene substituted nitrile is allowed to react with an R, azide in the presence of a base to provide the desired 5-amino-1-substituted-1,2,3-triazole.
  • the reaction is carried out in solvents such as aromatic hydrocarbons, lower alkanols, dimethylformamide, dimethylsulphoxide or hexamethylphosphortriamide.
  • the base may be any alkali metal or alkaline-earth metal hydroxide, alkoxide or hydride such as sodium ethoxide, potassium t-butoxide, magnesium ethoxide, sodium hydroxide or sodium hydride, chosen to be compatible with the reaction solvent.
  • reaction is conducted at from -40°C to 100°C and is complete in from 15 minutes to 48 hours.
  • the product of the reaction is isolated by known techniques.
  • X is a halogen, preferably chlorine or bromine.
  • a 1-unsubstituted but otherwise appropriately substituted 1,2,3-triazole is reacted with an R 1 halide in the presence of a base to prepare the desired 1- substituted 1,2,3-triazole.
  • the reaction is carried out in a solvent which may be any polar aprotic organic solvent such as dimethylformamide, dimethylsulphoxide, acetonitrile or dioxane in the presence of a base, which may be any non-nucleophilic organic or inorganic base.
  • Suitable inorganic bases are alkali metal bases, such as sodium and potassium carbonates, phosphates, bicarbonates and hydroxides, and sodium hydride.
  • the base is chosen for compatibility with the reaction solvent.
  • Suitable organic bases are tertiary amines such as trialkyl-substituted amines.
  • the reaction rate varies greatly with the nature of the proposed substituent at the R 1 position, the base and the solvent. Very reactive substituent and base combinations may take as little as ten minutes: at the other extreme, the reaction may take as long as two weeks. Most reactions are however complete in from 1 to 100 hours.
  • the reaction is carried out at a temperature of from room temperature to 100°C or to the reflux temperature of the solvent system being used.
  • the products of the reaction are isolated using known techniques.
  • novel compounds of this invention are orally administered to poultry for the control and prevention of coccidiosis.
  • Any number of conventional methods are suitable for administering the coccidiostats of this invention to poultry, for example, they may be given in the poultry feed, which is most convenient, or their drinking water.
  • the actual quantity of the coccidiostats administered to the poultry and the concentration in the feed will vary over a wide range and be adjusted to individual needs, depending upon species of the coccidia involved and severity of the infection. The limiting criteria are that the minimum amount be sufficient to control coccidiosis and the maximum amount be such that the coccidiosis does not cause any undesirable effects.
  • a feed typically contains from 0.001 to 0.2 percent, preferably from 0.003 to 0.1 percent, by weight of one of the coccidiostats of this invention.
  • the optimum levels will naturally vary with the specific compound utilized and species of Eimeria involved, and can be readily determined by one skilled in the art.
  • Levels of from 0.003 to 0.1 percent by weight of the diet are especially useful in controlling the pathology associated with E. tenella, as well as the intestinal dwelling species.
  • levels as low as 0.001 percent possess the novel effects of reducing the number of oocysts passed in the droppings of infected chickens.
  • novel coccidiostats of the invention may be readily dispersed by mechanically mixing them in finely ground form with the poultry feed, or with an intermediate formulation (premix) that is subsequently blended with other components to prepare the final poultry feed.
  • Typical components of poultry feeds include molasses, fermentation residues, corn meal, ground and rolled oats, wheat shorts and middlings, alfalfa, clover and meat scraps, together with mineral supplements such as bone meal and calcium carbonate and vitamins.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  • This invention relates to triazole compounds, their preparation, and their use.
  • Various 5-amino-4-substituted 1,2,3-triazoles with a 5-N-aryl or 1-aryl substituent are disclosed in II Farmaco, Vol 34, No 3, 1979, pages 217-228, and Vol 35, No 4, 1980, pages 298-307 and 308-232; in J.C.S. (1971) No 4, pages 706-713, (1969) No 1, 152-160 and (1974) No 17, pages 2030-2036; and in Chem. Abs., Vol 91 No 24, 204219s.
  • Coccidiosis is a wide-spread poultry disease which is produced by infections of protozoa of the genus Eimeria which causes severe pathology in the intestines and caeca of poultry. Some of the most significant of these species are e. tenella, E. acervulina, E. necatrix, E. brunetti, E. maxima, E. mitis, E. mivati, E. hagani and E. praecox. This disease is generally spread by the birds picking up the infectious organism in droppings on contaminated litter or ground or by way of food or drinking water. The disease is manifested by hemorrhage, accumulation of blood in the caeca, passage of blood to the droppings, weakness and digestive disturbances. The disease often terminates in death, but the market value of fowls that survive severe infections is substantially reduced. Coccidiosis is therefore a disease of great economic importance and extensive work has been done to find new and improved methods for controlling and treating coccidial infections in poultry.
  • None of the 1,2,3-triazole compounds in the documents mentioned above has any anti-coccidial activity, although US Patent Specification US-A-3 577 553 discloses the anti-coccidial nature of certain 1,3,4-triazoles, viz. compounds of the formula
    Figure imgb0001
    where Tz is 1,3,4-triazol-1-yl, R is hydrogen, C1-5 alkyl or C1-5 haloalkyl, and Ar is a phenyl or styryl radical, optionally having one or two C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, trifluoromethyl, trifluoromethoxy, nitro or halogen substituents in the ring.
  • The invention is based on the discovery that certain 5-amino-1,2,3-triazoles and their substituted derivatives have a surprisingly and unexpectedly high degree of activity against coccidiosis of poultry. Certain of the compounds are novel.
  • The compounds used anti-coccidially in accordance with this invention have the following structural formula:
    Figure imgb0002
    in which R1 is phenyl or phenyl-(C1-3 alkyl), either unsubstituted or having from one to five halogen, cyano, trifluoromethyl, C1-3 alkanoyl, nitro, C1-3 alkyl, C1-3 alkoxy, carboxy, alkyoxycarbonyl, trifluoromethoxy, acetamido, C1-3 alkylthio, C1-3 alkylsulphinyl, C1-3 alkylsulphonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulphinyl and/or trifluoromethylsulphonyl substituents; or is phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthylmethyl, quinolyl or quinolylmethyl; R2 is amino, C1-3 alkylamino, di(C1-3 alkyl)amino, acetamido, acetamido, ureido, formamido, formimido or guanidino; and R3 is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl.
  • In the novel compounds of the present invention, R1 is a benzyl radical having a trichlorovinyl substituent and none, one or two substituents as defined above, all the substituents being in the meta or para position.
  • Preferably, in the anticoccidial compounds R2 is amino, R3 is carbamoyl, and R1 is phenyl or benzyl having one, two or three substituents that are halogen, cyano, trifluoromethyl, trichlorovinyl and/or methyl; especially di- or substituted phenyl or di- or tri-substituted benzyl in which the substituents are in the meta or para positions and are chloro, cyano, methyl, trifluoromethyl, or trichlorovinyl.
  • Examples of preferred compounds for anti-coccidial use in accordance with this invention are:
    • 5-amino-1-(3,4-dichlorobenzyl)-1,2,3-triazole-4-carboxamide,
    • 5-amino-1-(3,4,5-trichlorobenzyl)-1,2,3-triazole-4-carboxamide,
    • 5-amino-1-(4-chloro-3-trifluoromethylbenzyl)-1,2,3-triazole-4-carboxamide,
    • 5-amino-1-(4-trichlorovinylbenzyl)-1,2,3-triazole-4-carboxamide. Only the last-mentioned is novel and per se forms part of the present invention.
  • The C1-3 alkyl groups comprise methyl, ethyl, propyl and isopropyl; the C1-3 alkoxy groups comprise methoxy, ethoxy, propoxy, and isopropoxy; the C1-3 alkanoyl groups comprise formyl, acetyl, and propionyl.
  • Administration of a small amount of at least one compound preferably by combination with poultry feed, is effective in preventing or greatly reducing the incidence of coccidiosis. The compounds are effective against both the caecal form (caused principally by E. tenella) and the intestinal forms (principally caused by E. acervulina, E. brunetti, E. maxima and E. necatrix). The coccidiostats of this invention are particularly effective against the species that caused caecal damage in addition to preventing the pathology caused by the coccidia. Compounds of the invention are also active against Eimeria spp, in other animals.
  • The compounds may be prepared by any one of several processes. The most general process is outlined in the following reaction scheme.
    Figure imgb0003
  • An R3-methylene substituted nitrile is allowed to react with an R, azide in the presence of a base to provide the desired 5-amino-1-substituted-1,2,3-triazole. The reaction is carried out in solvents such as aromatic hydrocarbons, lower alkanols, dimethylformamide, dimethylsulphoxide or hexamethylphosphortriamide. The base may be any alkali metal or alkaline-earth metal hydroxide, alkoxide or hydride such as sodium ethoxide, potassium t-butoxide, magnesium ethoxide, sodium hydroxide or sodium hydride, chosen to be compatible with the reaction solvent. Generally the reaction is conducted at from -40°C to 100°C and is complete in from 15 minutes to 48 hours. The product of the reaction is isolated by known techniques.
    Figure imgb0004
    where X is a halogen, preferably chlorine or bromine. A 1-unsubstituted but otherwise appropriately substituted 1,2,3-triazole is reacted with an R1 halide in the presence of a base to prepare the desired 1- substituted 1,2,3-triazole. The reaction is carried out in a solvent which may be any polar aprotic organic solvent such as dimethylformamide, dimethylsulphoxide, acetonitrile or dioxane in the presence of a base, which may be any non-nucleophilic organic or inorganic base. Suitable inorganic bases are alkali metal bases, such as sodium and potassium carbonates, phosphates, bicarbonates and hydroxides, and sodium hydride. The base is chosen for compatibility with the reaction solvent. Suitable organic bases are tertiary amines such as trialkyl-substituted amines. The reaction rate varies greatly with the nature of the proposed substituent at the R1 position, the base and the solvent. Very reactive substituent and base combinations may take as little as ten minutes: at the other extreme, the reaction may take as long as two weeks. Most reactions are however complete in from 1 to 100 hours. The reaction is carried out at a temperature of from room temperature to 100°C or to the reflux temperature of the solvent system being used. The products of the reaction are isolated using known techniques.
  • The novel compounds of this invention are orally administered to poultry for the control and prevention of coccidiosis. Any number of conventional methods are suitable for administering the coccidiostats of this invention to poultry, for example, they may be given in the poultry feed, which is most convenient, or their drinking water. The actual quantity of the coccidiostats administered to the poultry and the concentration in the feed will vary over a wide range and be adjusted to individual needs, depending upon species of the coccidia involved and severity of the infection. The limiting criteria are that the minimum amount be sufficient to control coccidiosis and the maximum amount be such that the coccidiosis does not cause any undesirable effects.
  • A feed typically contains from 0.001 to 0.2 percent, preferably from 0.003 to 0.1 percent, by weight of one of the coccidiostats of this invention. The optimum levels will naturally vary with the specific compound utilized and species of Eimeria involved, and can be readily determined by one skilled in the art. Levels of from 0.003 to 0.1 percent by weight of the diet are especially useful in controlling the pathology associated with E. tenella, as well as the intestinal dwelling species.
  • Depending on the compound used, levels as low as 0.001 percent possess the novel effects of reducing the number of oocysts passed in the droppings of infected chickens.
  • The novel coccidiostats of the invention may be readily dispersed by mechanically mixing them in finely ground form with the poultry feed, or with an intermediate formulation (premix) that is subsequently blended with other components to prepare the final poultry feed. Typical components of poultry feeds include molasses, fermentation residues, corn meal, ground and rolled oats, wheat shorts and middlings, alfalfa, clover and meat scraps, together with mineral supplements such as bone meal and calcium carbonate and vitamins.
  • The following non-limiting examples will serve to further illustrate the invention.
  • Example 1 5-Amino-1-(3,4-dichlorobenzyl)-1,2,3-triazole-4-carboxamide Method A
  • A stirred mixture of 3,4-dichlorobenzyl chloride (12.6 g, 64.5 mmol) and sodium azide (7.0 g, 0.11 mole) in absolute ethanol (70 ml) was refluxed for 4.75 hours, cooled and filtered to provide a solution of 3,4-dichlorobenzyl azide. Separately, 2-cyanoacetamide (5.5 g, 65 mmol) was added to a 35°C solution of sodium (1.5 g, 65 mmol) in absolute ethanol (125 ml), and to the resulting suspension was added the above azide solution dropwise over 10 minutes. The combined mixtures were refluxed for 1 hour, kept 16 hours at ambient temperature and 1 hour at 5°C, and filtered. The crude product was dried under vacuum, dissolved in boiling ethanol (290 ml), filtered hot, and cooled to 0°C. The solid was collected by filtration and dried under vacuum to provide 12.4 g (67%) of 1-(3,4-dichlorobenzyl)-5-amino-1,2,3-triazole-4-carboxamide, m.p. 221-222°C.
  • Method B
  • A stirred, ambient temperature solution of 5-amino-1,2,3-triazole-4-carboxamide (635 mg, 5.00 mole) in dry dimethylformamide (20 ml) is treated in one portion with sodium hydride (240 mg of a 50% dispersion in mineral oil, 120 mg NaH, 5.0 mmol). After 15 min 3,4-dichlorobenzyl chloride (0.977 g, 5.00 mmol) is added. The mixture is stirred 1 hour, poured into water (20 ml), acidified to pH 6 with glacial acetic acid, and filtered. The solid is washed with water, dried, and chromatographed to provide 5-amino-1-(3,4-dichlorobenzyl)-1,2,3-triazole-4-carboxamide.
  • Example 2 5-Amino-1-(4-methylbenzyl)-1,2,3-triazole-4-carboxamide
  • A stirred mixture of 4-methylbenzyl bromide (1.3 g, 7.0 mmol) and sodium azide (754 mg, 11.6 mole) in ethanol (8 ml) was refluxed under a nitrogen atmosphere for 3 hours, cooled to ambient temperature, and filtered. Separately, 2-cyanoacetamide (588 mg, 7.0 mmol) was added to a stirred, refluxing solution of sodium (167 mg, 7.2 mmol) in ethanol (15 ml), followed by dropwise addition of the above azide solution over 20 min. The resulting slurry was refluxed 1 hour, cooled to ambient temperature, and refrigerated. The precipitate was collected by filtration, washed with ethanol, and dried under vacuum to provide 1.12 g (69%) of 1-(4-methylbenzyl)-5-amino-1,2,3-triazole-4-carboxamide, m.p. 223-225°C.
  • Example 3 4-Chloro-3-cyanobenzyl bromide
  • A mixture of 2-chloro-5-methylbenzonitrile (10.6 g, 69.9 mmol), N-bromosuccinimide (12.2 g, 68.5 mmol) and dibenzoyl peroxide (349 mg, 1.44 mmol) in benzene (350 ml) was refluxed 1.5 hours, cooled, and evaporated to dryness under vacuum. The residue was suspended in 7:3 (v/v) hexane-dichloromethane, filtered, and evaporated. The crude product was chromatographed on silica gel (650 g) eluted with 7:3 (v/v) hexane-dichloromethane to provide 4.8 g (30%) 4-chloro-3-cyanobenzyl bromide, m.p. 55-58°C.
  • Example 4 4-Chloro-3-cyanobenzyl azide
  • A stirred mixture of 4-chloro-3-cyanobenzyl bromide (3.0 g, 13 mmol), and sodium azide (1.26 mg, 19.4 mmol) was refluxed 5 hours in absolute ethanol (30 mL). The mixture was kept 18 hours at ambient temperature, filtered, and the filtrate was evaporated under vacuum. The residue was triturated with diethyl ether, filtered, and evaporated to provide 2.45 g (98%) liquid 4-chloro-3-cyanobenzyl azide; I.R. (neat): 2240, 2100 cm'.
  • Example 5 5-Amino-1-(4-chloro-3-cyanobenzyl)-1,2,3-triazole-4-carboxamide
  • A stirred suspension of 2-cyanoacetamide (790 mg, 9.40 mmol) in absolute ethanol (40 ml) was treated with sodium methoxide (495 mg, 9.16 mmol) and refluxed 10 minutes. The mixture was cooled slightly, a solution of 4-chloro-3-cyanobenzyl azide (1.35 g, 7.01 mmol) in absolute ethanol (10 ml) was added in one portion, and the mixture was refluxed 2.5 hours. The mixture was filtered hot, the solid was washed with absolute ethanol, and the combined filtrate and wash were evaporated to dryness under vacuum. The residue was triturated with diethyl ether, filtered, and washed twice with diethyl ether. The solid was recrystallized from methanol (6 ml) and dried at 65°C under vacuum to provide 635 mg (24%) 5-amino-1-(4-chloro-3-cyanobenzyl)-1,2,3-triazole-4-carboxamide, m.p. 172-175°C.
  • Example 6 1-(3,4-Dichlorobenzyl)-5-methylamino-1,2,3-triazole-4-carboxamide
  • A mixture of 5-amino-1-(3,4-dichlorobenzyl)-1,2,3-triazole-4-carboxamide (2.66 g, 10.0 mmol), methyl iodide (1.42 g, 10.0 mmol), and potassium carbonate (1.38 g, 10.0 mmol) in N,N-dimethylformamide (20 ml) is stirred 48 hours at ambient temperature, poured into water (150 ml), and filtered. Chromatography provides 1-(3,4-dichlorobenzyl)-5-methylamino-1,2,3-triazole-4-carboxamide.
  • Example 7 5-Amino-1-(4-chloro-3-cyanobenzyl)-1,2,3-triazole-4-carboxamide
  • A stirred suspension of 2-cyanoacetamide (790 mg, 9.4 mmol) in absolute ethanol (40 ml) was treated with sodium methoxide (495 mg, 9.2 mmol) and refluxed 10 minutes. The mixture was cooled lightly, a solution of 4-chloro-3-cyanobenzyl azide (1.35 g, 7.0 mmol) in absolute ethanol was added, and the mixture was refluxed 2.5 hours. The mixture was filtered hot, and the filtrate evaporated under vacuum. The residue was triturated with diethyl ether, filtered, and washed twice with diethyl ether. The solid was recrystallized from refluxing methanol, filtered, washed twice with methanol and once with diethyl ether, and dried at 65°C under vacuum to provide 635 mg (33%) 5-amino-1-(4-chloro-3-cyanobenzyl)-1,2,3-triazole-4-carboxamide, m.p. 172-175°C.
  • Example 8 5-Amino-1-(4-cyano-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide
  • A stirred, ambient temperature solution of 5-amino-1,2,3-triazole-4-carboxamide (630 mg, 5.0 mmol) in dry N,N-dimethylformamide (20 ml) was treated with sodium hydride (250 mg of a 50% dispersion in mineral oil, 125 mg NaH, 5.2 mmol). The resulting suspension was stirred 10 min., 4-cyano-3,5-dichlorobenzyl chloride (1.1 g, 5.0 mmol) was added, and the mixture was stirred 2 hours. The reaction was quenched by pouring into ice and water (80 ml). The suspension was filtered and washed three times with water. The solid was suspended in 19:1 (v/v) dichloromethane-methanol and filtered to provide 364 mg (23%) 5-amino-1-(4-cyano-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide. Recrystallization from ethanol provided material of m.p. 238-239.5°C.

Claims (9)

1. A compound having the formula:
Figure imgb0005
in which R1 is a benzyl radical having a trichlorovinyl substituent and none, one or two halogen, cyano, trifluoromethyl, C1-3 alkanoyl, nitro, C1-3 alkyl, Ci-3 alkoxy, carboxy, alkoxycarbonyl, trifluoromethoxy, acetamido, C1-3 alkylthio, C1-3 alkylsulphinyl, C1-3 alkylsulphonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulphinyl and/ortrifluoromethylsulphonyl substituents; R2 is amino, C1-3 alkylamino, d(C1-3 alkyl)amino, acetamido, ureido, formamido, formimido or guanidino; and R3 is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl.
2. A compound as claimed in Claim 1 in which R1 is a benzyl radical having a trichlorovinyl substituent and none, one or two substituents that are halogen, cyano, trifluoromethyl, trichlorovinyl and/or methyl; R2 is amino and R3 is carbamoyl.
3. 5-amino-1-(4-trichlorovinylbenzyl)-1,2,3-triazole-4-carboxamide.
4. A method of preparing a compound as claimed in Claim 1 in which R2 is amino by reaction of a monosubstituted acetonitrile R3CH2CN with an azide R1N3 in the presence of an alkali metal or alkaline-earth metal hydroxide, alkoxide or hydride in a compatible solvent.
5. A method as claimed in claim 4 in which the monosubstituted acetonitrile is 2-cyanoacetamide, malononitrile, or a lower alkyl ester of cyanoacetic acid.
6. A method of preparing a compound as claimed in Claim 1 comprising reacting a compound as claimed in Claim 1 except that R1 is hydrogen with an R1 halide in the presence of a non-nucleophilic organic or inorganic base and in a compatible polar aprotic organic solvent.
7. A method of preparing a compound as claimed in Claim 1 in which R2 is C1-3 alkyl amino or di(C1-3 alkyl)amino comprising reacting a compound as claimed in Claim 1 in which R2 is amino with a C1-3 alkyl halide in the presence of a non-nucleophilic organic or inorganic base and in a compatible polar aprotic organic solvent.
8. A compound having the formula
Figure imgb0006
in which R, is phenyl or phenyl-(C1-3alkyl), either unsubstituted or having from one to five halogen, cyano, trifluoromethyl, C1-3 alkanoyl, nitro, C1-3 alkyl, C1-3 alkoxy, carboxy, alkoxycarbonyl, trifluoromethoxy, acetamido, C1-3 alkylthio, C1-3 alkylsulphinyl, C1-3 alkylsulphonyl, trichlorovinyl, trifluoromethylthio, trifluoromethylsulphinyl and/or trifluoromethylsulphonyl substituents; or is phenacyl, pyridyl, pyridylmethyl, naphthyl, naphthylmethyl, quinolyl or quinolylmethyl; R2 is amino, C1-3 alkylamino, di(C1-3 alkyl) amino, acetamido, ureido, formamido, formimido or guanidino; and R3 is carbamoyl, cyano, carbazoyl, amidino or N-hydroxycarbamoyl, for use in the prevention or treatment of coccidiosis.
9. A composition useful for the prevention and treatment of coccidiosis which comprises an inert carrier and a compound having the formula set forth in Claim 8.
EP85300520A 1984-02-02 1985-01-25 5-(amino or substituted amino)-1,2,3-triazoles Expired - Lifetime EP0151528B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57630284A 1984-02-02 1984-02-02
US576302 1984-02-02

Publications (3)

Publication Number Publication Date
EP0151528A2 EP0151528A2 (en) 1985-08-14
EP0151528A3 EP0151528A3 (en) 1986-04-02
EP0151528B1 true EP0151528B1 (en) 1990-07-04

Family

ID=24303845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85300520A Expired - Lifetime EP0151528B1 (en) 1984-02-02 1985-01-25 5-(amino or substituted amino)-1,2,3-triazoles

Country Status (6)

Country Link
EP (1) EP0151528B1 (en)
JP (1) JPH0625171B2 (en)
AU (2) AU3829985A (en)
DE (1) DE3578499D1 (en)
NZ (1) NZ210983A (en)
ZA (1) ZA85785B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129244B2 (en) 2003-09-18 2006-10-31 Conforma Therapeutics Corporation Triazolopyrimidines and related analogs as HSP90-inhibitors
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752611A (en) * 1985-11-29 1988-06-21 Merck & Co., Inc. Anticoccidial 1,2,3-trazole compounds
EP0229011A1 (en) * 1986-01-06 1987-07-15 Ciba-Geigy Ag Trisubstituted triazoles
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
US5880129A (en) * 1989-05-19 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting invasion and metastasis of malignant solid tumors
US5498620A (en) * 1989-05-19 1996-03-12 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor 1,2,3-triazolo compounds
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577553A (en) * 1969-01-29 1971-05-04 Smith Kline French Lab Compositions and methods for controlling coccidiosis in poultry employing triazole derivatives
DE3369845D1 (en) * 1982-12-20 1987-04-02 Merck & Co Inc 5-(amino or substituted amino) imidazoles
FI834666A (en) * 1982-12-23 1984-06-24 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR.
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
FI93544C (en) * 1985-04-18 1995-04-25 Ciba Geigy Ag Process for the preparation of fluorinated 1-benzyl-1H-1,2,3-triazole compounds with anticonvulsant action

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7129244B2 (en) 2003-09-18 2006-10-31 Conforma Therapeutics Corporation Triazolopyrimidines and related analogs as HSP90-inhibitors
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
US7148228B2 (en) 2003-09-18 2006-12-12 Conforma Therapeutics Corporation Pyrazolopyrimidines and related analogs as HSP90-inhibitors
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
US8093229B2 (en) * 2005-03-30 2012-01-10 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors

Also Published As

Publication number Publication date
JPS60188375A (en) 1985-09-25
AU598067B2 (en) 1990-06-14
AU3829985A (en) 1985-09-12
ZA85785B (en) 1986-09-24
EP0151528A2 (en) 1985-08-14
NZ210983A (en) 1989-11-28
JPH0625171B2 (en) 1994-04-06
EP0151528A3 (en) 1986-04-02
DE3578499D1 (en) 1990-08-09
AU8203087A (en) 1988-03-24

Similar Documents

Publication Publication Date Title
EP0151529B1 (en) 5-(amino or substituted amino)-1,2,3-triazoles
EP0150937B1 (en) Dihydropyridazinones
US4659720A (en) 5-amino or substituted amino imidazoles useful to treat coccidiosis
EP0151528B1 (en) 5-(amino or substituted amino)-1,2,3-triazoles
US4622330A (en) Antiprotozoal 3-amino or substituted amino pyrazoles
EP0113570B1 (en) 5-(amino or substituted amino) imidazoles
US4946842A (en) Novel guanidino pyridazinones as cardiac stimulants
US4407802A (en) 6-Amidino-9-substituted benzyl purines
US4816469A (en) 5-Amino or substituted amino 1,2,3-triazoles
IE861015L (en) Triazoles
US4950673A (en) 5-amino or substituted amino 1,2,3-triazoles
US3560496A (en) 2-benzyl-as-triazine-3,5(2h,4h) diones
US3020200A (en) 1-(2-alkyl-4-amino-5-pyrimidinylmethyl)-alkyl-pyridinium quaternary salts for treating coccidiosis
US4721791A (en) 5-amino or substituted amino 1,2,3-triazoles
US4752611A (en) Anticoccidial 1,2,3-trazole compounds
US4294842A (en) Anti-protozoal oxadiazole derivatives
US4766123A (en) Methylamidine compounds
EP0199465A2 (en) Cyanoalkanimidamido compounds
US4311710A (en) Anticoccidial formulation and method
US3926935A (en) Anticoccidial complexes
US4083984A (en) 1-Substituted phenyl-4(1H)-pyridinone hydrazones and composition therewith for treatment of coccidiosis
US4130661A (en) Substituted benzoylacrylanilides
US4044133A (en) Anticoccidial compositions
US3439019A (en) N-benzoyloxymethyl benzamides and their preparation
US3968228A (en) 4-Nitro-5-cyanoimidazoles as coccidiostats

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): CH DE FR GB IT LI NL

ITCL It: translation for ep claims filed

Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): CH DE FR GB IT LI NL

17P Request for examination filed

Effective date: 19860820

17Q First examination report despatched

Effective date: 19871127

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE FR GB IT LI NL

REF Corresponds to:

Ref document number: 3578499

Country of ref document: DE

Date of ref document: 19900809

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19921216

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19921228

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19921231

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19930131

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19930226

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19940125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19940131

Ref country code: CH

Effective date: 19940131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19940801

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19940125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19940930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19941001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST